Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin

Diabetes Care

Volumn 28, Issue 5, 2005, Pages 1077-1082

  Rave, Klaus ^a   Bott, Susanne ^a   Heinemann, Lutz ^a   Sha, Sue ^b   Becker, Reinhard H A ^c   Willavize, Susan A ^b   Heise, Tim ^a  

^a Profil Inst F S   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN LISPRO; NEUTRAL INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, INHALATION; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; GLUCOSE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; TIME FACTORS;

EID: 18144368866     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.5.1077     Document Type: Article

References (24)

1. Heinemann L, Traut T, Heise T: Time-action profile of inhaled insulin. Diabet Mid 14:63-72, 1997
2. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR: Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 44:305-308, 2001
3. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, Heinemann L: Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 25:2276-2281, 2002
4. Patton JS, Bukar JG, Eldon MA: Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43:781-801, 2004
5. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K: Technosphere/insulin - proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 110:17-21, 2002
6. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 13:625-629, 1996
7. Zambanini A, Newson RB, Maisey M, Feher MD: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 46:239-246, 1999
8. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134:203-207, 2001
9. Jendle JH, Karlberg BE: Intrapulmonary administration of insulin to healthy volunteers. J Intern Med 240:93-98, 1996
10. Jendle JH, Karlberg BE: Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 56:555-561, 1996
11. Howey DC, Bowsher RR, Brunelle RL, WoodworthJR: [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402, 1994
12. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T: Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 21:1910-1914, 1998
13. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, Brunetti P, Bolli GB: Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15:592-600, 1998
14. 1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795-800, 1999
15. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T: Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23:1343-1347, 2000
16. Galloway JA, Root MA, Rathmacher RP, Carmichael RH: A comparison of acid regular and neutral regular insulin: responses of normal fasted subjects to varying doses of regular insulin. Diabetes 22:471-479, 1973
17. Heinemann L, Woodworth JR: Pharmacokinetics and metabolism of insulin lispro. Drugs Today 34 (Suppl. C):23-36, 1998
18. Sapin R: Insulin assays: previously known and new analytical features. Clin Lab 49:113-121, 2003
19. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357:331-335, 2001
20. Quattrin T, Bélanger A, Bohannon NJV, Schwartz SL: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2622-2627, 2004
21. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson J-L, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes mellitus: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2356-2362, 2004
22. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA: Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 24:1556-1559, 2001
23. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides A, Gerber RA: Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 24:552-564, 2002
24. Skyler J: Sustained long-term efficacy and safety of inhaled insulin (Exubera) during 4 years of continuous therapy (Abstract). Diabetes 53 (Suppl. 2):A115, 2004